Frequency Therapeutics (FREQ) R&D Event

Frequency Therapeutics (FREQ) R&D Event

November 9, 2021

Frequency Therapeutics (FREQ) hosted a virtual R&D event on Tuesday, November 9th, 2021. The program included an update on advances for the Company’s FX-322 program for sensorineural hearing loss, as well as new potential restorative treatment programs for hearing loss and remyelination in multiple sclerosis.

Frequency Therapeutics (FREQ) R&D Event
Full Webcast
Presentation Slides
  Press Release
Transcript
Strategic Company overview
Strategic Company overview
David L. Lucchino
Chief Executive Officer
Pioneering a new category in regenerative medicine
Pioneering a new category in regenerative medicine
Robert S. Langer, ScD
Frequency Therapeutics co-founder and MIT Institute Professor
Key learnings from FX-322 hearing restoration program and clinical development path
Key learnings from FX-322 hearing restoration program and clinical development path
Carl LeBel, PhD
Chief Development Officer
FX-322 clinical data and real-world impact of speech perception improvements
FX-322 clinical data and real-world impact of speech perception improvements
Kevin Franck, PhD
SVP, Strategic Marketing and New Product Planning
Cochlear pathology and the impact of high frequencies on speech perception
Cochlear pathology and the impact of high frequencies on speech perception
Sumit Dhar, PhD
Hugh Knowles Professor of Hearing Science and Associate Provost for Faculty at Northwestern University
Clinical Development Path for Hearing Restoration Program
Clinical Development Path for Hearing Restoration Program
Carl LeBel, PhD
Chief Development Officer
Best-practice approaches for addressing placebo response in clinical trials
Best-practice approaches for addressing placebo response in clinical trials
Steven D. Targum, MD
Independent Consultant
New regenerative programs from continued progenitor cell activation (PCA) research and a new hearing program for sensory hair cell regeneration
Advances in progenitor cell activation (PCA) research and a new hearing program for sensory hair cell regeneration
Christopher Loose, PhD
Chief Scientific Officer
Remyelination for Multiple Sclerosis: Discovery of a novel target with exceptional in vivo activity
Remyelination for Multiple Sclerosis: Discovery of a novel target with exceptional in vivo activity
Sanjay Magavi, PhD
VP, Myelination Research